Binding agents which inhibit myostatin

Details Binding agents which inhibit myostatin Binding agents which inhibit myostatin

2011-04-19

2011-04-19

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S326000, C530S350000, C435S069100, C435S069700

Reexamination Certificate

active

07928075

ABSTRACT:
The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

REFERENCES:
patent: 6284882 (2001-09-01), Wu-Wong et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 7442778 (2008-10-01), Gegg et al.
patent: 7511012 (2009-03-01), Han et al.
patent: 7655764 (2010-02-01), Gegg et al.
patent: 7655765 (2010-02-01), Gegg et al.
patent: 7662931 (2010-02-01), Gegg et al.
patent: 2003/0140356 (2003-07-01), Bass et al.
patent: 2004/0087778 (2004-05-01), Feige et al.
patent: 2006/0140934 (2006-06-01), Gegg et al.
patent: 2 333 706 (1999-08-01), None
patent: WO 93/06843 (1993-04-01), None
patent: WO 99/02667 (1999-01-01), None
patent: WO 99/56768 (1999-11-01), None
patent: WO 00/07038 (2000-02-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 00/77206 (2000-12-01), None
patent: WO 01/53350 (2001-07-01), None
patent: WO 02/09641 (2002-02-01), None
Dedman et al., “Selection of Targeted Biological Modifiers from a Bacteriophage Library of Random Peptides,”J Biol Chem268(31):23025-23030, 1993.
Hill et al., “The Myostatin Propeptide and the Follistatin-related Gene are Inhibitory Binding Proteins of Myostatin in Normal Serum,”J Biol Chem277(43):40735-40741, 2002.
Lee et al., “Regulation of myostatin activity and muscle growth,”Proc Natl Acad Sci USA98:9306-9311, 2001.
McPherron et al., “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,”Nature387:83-90, 1997.
McPherron and Lee, “Double muscling in cattle due to mutations in the myostatin gene,”Proc Natl Acad Sci USA94:12457-12461, 1997.
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand, eds., Birkhauser, Boston, pp. 491-495.
Thies et al., “GDR-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding,”Growth Factors18(4):251-259, 2001.
Wells, “Additivity of Mutational Effects in Proteins,”Biochemistry29(37):8509-8517, 1990.
Zachwieja et al., “Plasma Myostatin-Immunoreactive Protein is Increased After Prolonged Bed Rest With Low-Dose T, Administration,”J Gravitational Physiology6(2):11-15, 1999.
Zimmers et al., “Induction of Cachexia in Mice by Systemically Administered Myostatin,”Science296:1486-1488, 2002.

Affiliated with

Also associated with

Rating

Binding agents which inhibit myostatin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Binding agents which inhibit myostatin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Binding agents which inhibit myostatin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2655880